Brief: AB Science Announced The Continuation Of The Phase 2 Study Evaluating Masitinib In Combination With Isoquercetin In Covid-19

AB Science SA

28/04/2022 07:17

April 28 (Reuters) - AB Science SA  ABS.PA :
    * REG-AB SCIENCE ANNOUNCED THE CONTINUATION OF THE PHASE 2
STUDY
EVALUATING MASITINIB IN COMBINATION WITH ISOQUERCETIN IN
COVID-19, FOLLOWING THE RECOMMENDATION OF THE DATA AND SAFETY
MONITORING BOARD (DSMB)
    * AB SCIENCE SA - PRIMARY OBJECTIVE IS TO IMPROVE CLINICAL
STATUS
OF PATIENTS AFTER 15 DAYS OF TREATMENT, AS MEASURED BY WHO
7-POINT ORDINAL SCALE.
    * AB SCIENCE SA - DSMB RECOMMENDS CONTINUING STUDY WITHOUT
RESTRICTIONS IN MODERATE PATIENTS (LEVEL 4, I.E. HOSPITALIZED
PATIENTS WITH OXYGEN SUPPLY <6 L/MIN WITH SPO2 MAINTAINED ≥92%).
    * AB SCIENCE SA - AB SCIENCE HAS MADE DECISION TO CONTINUE
STUDY
ONLY IN MODERATE PATIENTS
    * AB SCIENCE SA - STUDY IS THEREFORE NOW PLANNED TO INCLUDE
200
PATIENTS AT LEVEL 4 OF ORDINAL SCALE

Source text for Eikon:  ID:nGNE3VJ5nD 
Further company coverage:  ABS.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))